• Search
  • Helpdesk
  • Sales contact

Kayentis finalized its round of funding in february

Last updated : June 24, 2024

Kayentis finalized in February 2015 a round of funding with the arrival of Extens, a fund dedicated to e-health, alongside Seventure Partners, a shareholder since 2007, and business angels (new and already present in the shareholdings).

Guillaume Juge, director of Kayentis, said, “we are very happy to welcome Extens, whose focus on e-health completes our repositioning on the pharma market.”

Arnaud Houette, managing director and associate of Extens exclaimed, “Kayentis has been able to reinvent itself and we have faith in Guillaume Juge to pursue the company’s transformation, particularly concerning international business development.”

About Extens (www.extens.eu)

Extens is an investment fund exclusively devoted to the e-health sector. Extens invests amounts ranging from 1 to 7 million euros in profitable SME’s or those soon to become profitable with a level of turnover between 1 and 20 million euros. Its core target: software applications for hospitals, business process software for health professionals and solutions to accompany home care or mobility. Kayentis is the second investment in its portfolio after Enovacom in March 2014.

About Seventure Partners (www.seventure.fr)

An active partner of innovative companies with high growth potential, Seventure Partners has been investing in two main fields of business since 1997: the digital economy in France and Germany, and life sciences throughout Europe. Managing more than €515M as of 31 December 2014, Seventure Partners has become one of the main European players in innovation capital. Seventure Partners is a subsidiary of Natixis Global Asset Management. Natixis is the bank of investment, management and financial services in the BPCE group.

Guillaume JUGE, CEO – Kayentis

Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

5th Annual Clinical Trial Innovation Summit

JUNE 26, 2025 • Basel, CH
Clinical Trial Innovation Summit 2025 | June 26, 2025

The reckless value of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET
In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....

DPHARM 2025

SEPT 16-17 2025 • Philadelphia, PA, USA
Booth #44 16th Annual Outsourcing in Clinical Trials East Coast 2025 - Arena International

SCDM 2025

Baltimore, Maryland, USA - 27-30 SEPT 2025
Annual Conference 2025 – SCDMLive    

SCOPE Europe 2025

OCT 14-15 2025 • Barcelona, Spain
SCOPE Europe | Summit for Clinical Operations Executives | October 14-15, 2025 |Barcelona, Spain